Best Buy Co Inc vs Novavax Inc — how do they compare? Best Buy Co Inc trades at $82.86 (market cap $17.55B), while Novavax Inc trades at $7.9 (market cap $1.31B). The key difference: Best Buy Co Inc is far larger — about 13.4× Novavax Inc's market cap, and Best Buy Co Inc pays a 4.61% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| BBY | NVAX | |
|---|---|---|
Market Cap | $17.55B | $1.31B |
Sector | Consumer Cyclical | Health |
52-Week High | $90.17 | $11.19 |
52-Week Low | $55.52 | $6.22 |
Enterprise Value | $19.93B | $889.30M |
Dividend Yield | 4.61% | — |
Signals from Pluang's Aura AI — not financial advice
BBY trades at $82.43, up 0.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 39.1% ROE and trades at a P/E of 15.42, below the sector average. Recent news includes leadership changes and store format tests aimed at growth.
Outlook is mixed: analyst consensus is a hold with a $84.31 price target, but risks include declining revenue and competitive pressures. Upside potential exists if new strategies boost sales, while downside is capped by solid cash flow and dividend payments.
Novavax (NVAX) trades at $7.89, down 0.75% on the day, with a bullish technical signal despite mixed indicators. The company reported a strong Q2 2026 earnings beat, raising its full-year revenue outlook, while maintaining a low valuation with a P/E of 3.14 and EV/EBITDA of 1.72. However, negative net income margin and shareholder equity highlight financial challenges.
The outlook is cautiously optimistic, driven by partnership milestones with Sanofi and cost reductions, but risks include persistent cash burn and competitive vaccine market pressures. Analyst consensus leans bullish with 74% buy ratings, suggesting potential upside if execution improves.
Trailing returns across standard periods
With $51.8 billion in fiscal 2022 sales, Best Buy is the largest pure-play consumer electronics retailer in the U.S., with roughly 10.6% share of the aggregate market and north of 40% share of offline sales, per our calculations, CTA industry, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the COVID-19 pandemic, have seen the U.S. e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.
Read more on BBY →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →